Ligand Pharmaceuticals Incorporated (LGND)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$298.50

+3.51 (+1.19%)

Market Cap: $5.88B

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

90%(35/39)

Avg Surprise

+41.95%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$2.31

Range$1.93 - $2.49

10 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$2.51-8.0%

60d ago$2.56-9.7%

30d ago$2.30+0.2%

7d ago$2.30+0.2%

Current$2.31

Revenue Consensus

$78M

Range$65M - $92M

11 analysts

Period ending Dec 31, 2026

EPS Consensus$3.22

Range$3.01 - $3.42

10 analysts

Revenue Consensus

$92M

Range$80M - $108M

11 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$3.22	$3.01 - $3.42	-	-	10	-	-
Sep 30, 2026Sep 26EST	-	$2.31	$1.93 - $2.49	-	-	10	0 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$2.22	$1.34	$0.75 - $2.25	+65.67%	Beat	9	0 2 30d	+825.0%
Mar 31, 2026Mar 26 Reported May 14, 2026Reported May 14	$1.63	$1.80	$1.66 - $1.96	-9.44%	Miss	6	0 4 30d	+22.6%
Dec 31, 2025Dec 25 Reported Feb 26, 2026Reported Feb 26	$2.12	$0.63	$0.31 - $0.77	+236.51%	Beat	7	3 1 30d	+66.9%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$3.09	$1.93	$1.60 - $2.09	+60.10%	Beat	6	2 1 30d	+67.9%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$0.24	$0.21	-	+14.29%	Beat	7	0 5 30d	-82.9%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$1.33	$1.21	$1.14 - $1.27	+9.92%	Beat	4	0 2 30d	+10.8%
Dec 31, 2024Dec 24 Reported Feb 27, 2025Reported Feb 27	$1.27	$1.19	$1.05 - $1.35	+6.71%	Beat	7	1 1 30d	-8.0%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$1.84	$1.35	$1.17 - $1.68	+36.30%	Beat	7	1 0 30d	+80.4%
Jun 30, 2024Jun 24 Reported Aug 6, 2024Reported Aug 6	$1.40	$1.06	$0.94 - $1.36	+32.08%	Beat	5	No revisions (30d)	-1.4%
Mar 31, 2024Mar 24 Reported May 7, 2024Reported May 7	$1.20	$0.83	$0.56 - $0.93	+44.58%	Beat	5	No revisions (30d)	-47.4%
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$1.38	$0.66	$0.63 - $0.68	+109.09%	Beat	4	No revisions (30d)	+1.5%
Sep 30, 2023Sep 23 Reported Nov 8, 2023Reported Nov 8	$1.02	$0.62	$0.46 - $0.70	+64.52%	Beat	4	No revisions (30d)	-22.1%
Jun 30, 2023Jun 23 Reported Aug 8, 2023Reported Aug 8	$1.42	$0.66	$0.61 - $0.68	+115.15%	Beat	4	1 0 30d	+37.9%
Mar 31, 2023Mar 23 Reported May 4, 2023Reported May 4	$2.28	$0.89	$0.52 - $1.13	+156.18%	Beat	5	1 0 30d	+200.0%
Dec 31, 2022Dec 22 Reported Feb 22, 2023Reported Feb 22	$1.36	$1.19	$1.04 - $1.30	+14.29%	Beat	4	1 0 30d	-24.4%
Sep 30, 2022Sep 22 Reported Nov 7, 2022Reported Nov 7	$1.31	$0.43	$0.38 - $0.46	+204.65%	Beat	5	No revisions (30d)	-17.1%
Jun 30, 2022Jun 22 Reported Aug 8, 2022Reported Aug 8	$1.03	$0.43	$0.06 - $0.70	+139.53%	Beat	5	No revisions (30d)	-36.8%
Mar 31, 2022Mar 22 Reported May 4, 2022Reported May 4	$0.76	$0.66	$0.44 - $0.89	+15.15%	Beat	6	No revisions (30d)	-46.1%
Dec 31, 2021Dec 21 Reported Feb 17, 2022Reported Feb 17	$1.80	$1.37	$1.33 - $1.43	+31.39%	Beat	6	No revisions (30d)	+11.1%
Sep 30, 2021Sep 21 Reported Nov 9, 2021Reported Nov 9	$1.58	$1.04	$0.88 - $1.31	+51.92%	Beat	6	No revisions (30d)	+51.9%
Jun 30, 2021Jun 21 Reported Jul 29, 2021Reported Jul 29	$1.63	$1.36	$1.10 - $1.53	+19.85%	Beat	6	2 0 30d	+63.0%
Mar 31, 2021Mar 21 Reported May 3, 2021Reported May 3	$1.41	$1.13	$1.05 - $1.19	+24.78%	Beat	6	1 0 30d	+58.4%
Dec 31, 2020Dec 20 Reported Feb 3, 2021Reported Feb 3	$1.62	$1.09	$0.82 - $1.17	+48.62%	Beat	6	No revisions (30d)	+128.2%
Sep 30, 2020Sep 20 Reported Oct 30, 2020Reported Oct 30	$1.04	$0.98	$0.84 - $1.07	+6.12%	Beat	6	6 0 30d	+112.2%
Jun 30, 2020Jun 20 Reported Aug 3, 2020Reported Aug 3	$1.00	$0.76	$0.65 - $0.97	+31.58%	Beat	6	No revisions (30d)	+47.1%
Mar 31, 2020Mar 20 Reported May 6, 2020Reported May 6	$0.89	$0.66	$0.59 - $0.82	+34.85%	Beat	6	No revisions (30d)	-23.3%
Dec 31, 2019Dec 19 Reported Feb 6, 2020Reported Feb 6	$0.71	$0.65	$0.58 - $0.68	+9.23%	Beat	4	1 0 30d	-58.2%
Sep 30, 2019Sep 19 Reported Nov 5, 2019Reported Nov 5	$0.49	$0.62	$0.54 - $0.65	-20.97%	Miss	4	No revisions (30d)	-62.9%
Jun 30, 2019Jun 19 Reported Jul 30, 2019Reported Jul 30	$0.68	$0.55	$0.38 - $0.65	+23.64%	Beat	4	No revisions (30d)	-73.7%
Mar 31, 2019Mar 19 Reported May 2, 2019Reported May 2	$1.16	N/A	-	-92.49%	Miss	2	2 0 30d	-25.2%
Dec 31, 2018Dec 18 Reported Feb 7, 2019Reported Feb 7	$1.70	$1.22	$1.15 - $1.24	+39.34%	Beat	5	2 0 30d	+29.8%
Sep 30, 2018Sep 18 Reported Nov 8, 2018Reported Nov 8	$1.32	$1.03	$0.98 - $1.08	+28.16%	Beat	5	No revisions (30d)	+91.3%
Jun 30, 2018Jun 18 Reported Aug 6, 2018Reported Aug 6	$2.59	$2.38	$2.37 - $2.39	+8.82%	Beat	2	No revisions (30d)	+286.6%
Mar 31, 2018Mar 18 Reported May 8, 2018Reported May 8	$1.55	$1.26	$0.53 - $1.35	+23.02%	Beat	5	1 0 30d	+171.9%
Dec 31, 2017Dec 17 Reported Feb 21, 2018Reported Feb 21	$1.31	$1.19	$1.06 - $1.20	+10.08%	Beat	5	4 0 30d	+4.8%
Sep 30, 2017Sep 17 Reported Nov 9, 2017Reported Nov 9	$0.69	$0.61	$0.51 - $0.75	+13.11%	Beat	5	No revisions (30d)	-
Jun 30, 2017Jun 17 Reported Aug 7, 2017Reported Aug 7	$0.67	$0.46	$0.40 - $0.58	+45.65%	Beat	5	1 0 30d	-
Mar 31, 2017Mar 17 Reported May 9, 2017Reported May 9	$0.57	$0.72	-	-20.83%	Miss	-	-	-
Dec 31, 2016Dec 16 Reported Feb 23, 2017Reported Feb 23	$1.25	$1.19	-	+5.04%	Beat	-	-	-

Dividends

Dividend Metrics

Forward Yield0.00%

Forward Annual Dividend$0.00

Payout Ratio0.00%

No dividend payments in the selected period.

Key Metrics

Valuation
P/E Ratio	32.95	EV/EBITDA	29.67x
Price/FCF	45.56x	FCF Yield	2.19%
Profitability
Profit Margin	67.90%	Operating Margin	13.50%
ROE	22.00%	ROIC	6.90%
Financial Health
Debt/Equity	1.16x	Interest Coverage	28.18x
Current Ratio	31.18x	Quick Ratio	30.96x
Trading Statistics
Beta	1.01	Avg Volume	274.38K
52-Week High	$326.63	52-Week Low	$175.89

Technical Indicators Dashboard

Moving Averages

SMA 10$300.49

SMA 20$300.77

SMA 50$292.54

SMA 200$246.42

EMA 10$300.40

EMA 20$298.91

EMA 50$293.64

EMA 200$253.30

MACD

Line: 2.42Signal: 3.21Hist: -0.79

ADX

ADX: 13.8+DI: 18.2-DI: 19.8

Aroon & PSAR

Aroon Up56.0

Aroon Down12.0

PSAR$283.51

Bollinger Bands

Upper Band$316.23

Lower Band$285.32

%B Position1028%(Upper)

Band Width0.43

RSI (14-Day)

Neutral

50.6

Momentum Oscillators

Stoch %K48.7

Stoch %D58.7

Williams %R-52.8

ROC (10d)-1.4%

Momentum-4.24

CCI (20d)-6.5

MFI (14d)53.8

Volatility Measures

ATR (14d)$10.63(3.6%)

StdDev (20d)7.73

Hist Vol33.8%(Moderate)

Volume Flow

VWAP$300.02

OBV8.8M

AD Line9.5M

CMF (20d)0.012

Volume Metrics

Avg Vol (20d)274.4K

Vol Ratio1.2x

VWMA (20d)$300.87

Pivot Points

R3$318.80

R2$312.96

R1$303.97

Pivot Point$298.13

S1$289.14

S2$283.30

S3$274.31

Advanced Oscillators

TSI7.64

Ultimate Osc51.4

KST49.68

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$63.69M	$51.72M	$59.67M	$115.46M	$47.63M	$45.33M	$42.81M	$51.81M	$41.53M	$30.98M	$28.10M	$32.87M
Cost of Revenue	$3.21M	$3.27M	$2.99M	$3.80M	$2.91M	$4.85M	$2.84M	$2.45M	$2.91M	$2.88M	$8.84M	$0
Gross Profit	$60.48M	$48.45M	$56.67M	$111.66M	$44.72M	$40.48M	$39.98M	$49.36M	$38.63M	$28.10M	$19.26M	$32.87M

Operating Expenses	$51.89M	$31.08M	$42.83M	$56.73M	$36.28M	$76.70M	$49.61M	$46.22M	$57.73M	$25.11M	$24.74M	$29.79M
R&D	$14.67M	$2.15M	$3.51M	$21.02M	$6.57M	$50.09M	$4.42M	$5.67M	$5.35M	$5.97M	$5.49M	$5.53M
SG&A	$29.12M	$20.84M	$25.03M	$28.45M	$20.18M	$18.80M	$25.61M	$24.48M	$17.62M	$10.95M	$15.99M	$14.66M
Operating Income	$8.59M	$17.37M	$13.84M	$54.93M	$8.44M	$-36,216,000	$-9,637,000	$3.14M	$-19,100,000	$2.99M	$-3,358,000	$3.08M

Interest Income	$19.05M	$10.52M	$28.46M	$11.67M	$2.56M	$-10,596,000	$-21,968,000	$3.75M	$-11,499,000	$112.79M	$17.72M	$-10,921,000
Interest Expense	$1.75M	$1.75M	$1.78M	$910,000	$1.15M	$867,000	$887,000	$741,000	$1.27M	$141,000	$131,000	$1,000
Income Before Tax	$64.30M	$-24,259,000	$56.78M	$141.14M	$11.22M	$-50,180,000	$-39,200,000	$-6,339,000	$-65,390,000	$113.45M	$17.10M	$-12,144,000
Income Tax Expense	$15.80M	$-10,914,000	$12.00M	$23.86M	$6.38M	$-7,729,000	$-8,112,000	$833,000	$-13,479,000	$27.31M	$-1,091,000	$-1,871,000

Net Income	$48.51M	$-13,345,000	$44.78M	$117.27M	$4.85M	$-42,451,000	$-31,088,000	$-7,172,000	$-51,911,000	$86.14M	$18.19M	$-10,273,000

EBITDA	$55.32M	$-25,040,000	$37.35M	$138.23M	$18.11M	$-30,079,000	$-7,581,000	$211,000	$-43,600,000	$9.97M	$10.75M	$7.44M
EBIT	$47.00M	$-33,036,000	$30.11M	$130.38M	$9.82M	$-38,717,000	$-16,345,000	$-9,352,000	$-52,623,000	$796,000	$1.63M	$-1,222,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about LGND

News

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B (LGND) Earnings, Actual EPS, EPS Estimates & Results

This article provides an overview of Ligand Pharmaceuticals, Inc. (LGND) earnings, including estimated and historical EPS and revenue data. The company's upcoming Q3 '26 earnings report is scheduled for November 5th...

Stocktwits•Sep 26, 2026 4:51 PM ET9/26/26•Neutral

Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals

Invesco Ltd. has reported a 6.1% beneficial ownership stake in Ligand Pharmaceuticals Inc., according to a recent SCHEDULE 13G SEC filing. This represents 1,218,846 shares of Ligand's common stock...

Stock Titan•Aug 13, 2026 2:39 PM ET8/13/26•Neutral

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals reported strong Q2 2026 results, driven by increased royalty revenue and adjusted earnings...

TradingView•Aug 6, 2026 5:09 PM ET8/6/26•Bullish

ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ligand Pharmaceuticals Incorporated (LGDN). It provides a detailed table including each ETF's market value, weight of LGDN in the fund, issuer...

TradingView•Jul 22, 2026 7:11 AM ET7/22/26•Neutral

LGND Valuation and Fair Value

P/E: 32.9x
Forward P/E: 24.8x
EV/EBITDA: 29.7x
P/FCF: 45.6x
PEG: 1.5x
P/B: 6.2x

See GNG's fair value

LGND Profitability: Margins, ROIC and FCF

Gross margin: 95.4%
Operating margin: 13.5%
Net margin: 67.9%
ROIC: 6.9%
ROE: 22.0%
FCF margin: 45.2%
FCF yield: 2.2%

LGND Competitors

Company	Ticker
Rhythm Pharmaceuticals Inc	RYTM
Immunovant Inc	IMVT
Kiniksa Pharmaceuticals Ltd	KNSA
Kodiak Sciences Inc	KOD
Centessa Pharmaceuticals PLC ADR	CNTA
Haemonetics Corporation	HAE
GRAIL, LLC	GRAL
CG Oncology, Inc. Common stock	CGON

Sector: Healthcare

LGND Analyst Ratings

Consensus: Buy
Analysts: 10
Strong Buy: 2
Buy: 8
Hold: 0
Sell: 0
Strong Sell: 0

LGND Bull Case vs Bear Case

Bull case

LGND converts 45.2% of revenue into free cash flow.
LGND has a 67.9% net profit margin.
LGND beat EPS estimates in 87.5% of its last 8 reported quarters.

LGND Earnings: Beat Rate and Next Report

Beat rate: 7 of 8 quarters (87.5%)
Average surprise: 52.5%
EPS estimate (fiscal period ending Sep 30, 2026): $2.31
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 1 down

LGND Dividend

Forward yield: 0.0%
Payout ratio: 0.0%

Frequently Asked Questions About LGND

Does LGND pay dividends?

Ligand Pharmaceuticals Incorporated (LGND) has a dividend payment track record. See the LGND dividend history page for its current payment status, TTM yield, and recorded payments.

What is LGND's P/E ratio?

Ligand Pharmaceuticals Incorporated has a price-to-earnings (P/E) ratio of 32.95.

What is LGND's market cap?

Ligand Pharmaceuticals Incorporated (LGND) has a market capitalization of $5.88B with a current stock price of $298.50.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In